Pfizer has just unveiled plans to buy Baxter International’s portfolio of marketed vaccines for $635 million.
Under the deal, the firm also gains a portion of the Baxter’s facility in Orth, Austria, where these vaccines are manufactured.
The move gives the US drug giant access to Baxter’s meningitis C jab NeisVac-C and FSME-IMMUN/TicoVac, a vaccine that helps protect against tick-borne encephalitis (TBE).
Pfizer said the transaction, which remains subject to all the normal closing conditions as well as regulatory approvals in several markets, shouldn’t have any impact on its 2014 financial guidance.
